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of an alternating magnetic ield (AMF). 
Most of the studies from the last two dec-
ades investigating in vivo oncothermia 
comprise biocompatible and biodegrad-
able iron oxide-based nanoplatforms. 
Currently, the only clinically approved 
magnetic hyperthermia (HT) therapy 
employs spherical aminosilane coated 
iron oxide nanoparticles (IONPs, namely, 
NanoTherm MagForce Nanotechnolo-
gies) to treat glioblastoma multiforme in 
patients and currently in clinical trial for 
prostate cancer.[1] The major drawback of 
this system is that it requires a very high 
concentration of IONPs to achieve the 
temperature needed to kill cancer cells 
(43–45  °C). This is mainly due to their 
low speciic absorption rate (SAR) value, 
which is a direct measure of the heating 
capacity of the MNPs under AMF.
Cubic-shaped IONPs (IONCs) repre-
sent by far the benchmark product available with SAR values 
higher than spherical IONPs speciically due to their particular 
cubic shape and anisotropy.[2–4] Furthermore, to improve the 
Nanoparticle-based magnetic hyperthermia is a well-known thermal therapy 
platform studied to treat solid tumors, but its use for monotherapy is limited 
due to incomplete tumor eradication at hyperthermia temperature (45 °C). It is 
often combined with chemotherapy for obtaining a more efective therapeutic 
outcome. Cubic-shaped cobalt ferrite nanoparticles (Co–Fe NCs) serve as 
magnetic hyperthermia agents and as a cytotoxic agent due to the known cobalt 
ion toxicity, allowing the achievement of both heat and cytotoxic efects from a 
single platform. In addition to this advantage, Co–Fe NCs have the unique ability 
to form growing chains under an alternating magnetic ield (AMF). This unique 
chain formation, along with the mild hyperthermia and intrinsic cobalt toxicity, 
leads to complete tumor regression and improved overall survival in an in vivo 
murine xenograft model, all under clinically approved AMF conditions. Numer-
ical calculations identify magnetic anisotropy as the main Co–Fe NCs’ feature to 
generate such chain formations. This novel combination therapy can improve 
the efects of magnetic hyperthermia, inaugurating investigation of mechanical 
behaviors of nanoparticles under AMF, as a new avenue for cancer therapy.
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heating capacity of these well exploited spherical or cubic 
shaped IONPs, researchers have completely or partially 
replaced, the iron moiety (Fe2+) with other ions including cobalt 
(Co2+), nickel (Ni2+), manganese (Mn2+), and zinc (Zn2+) leading 
to exploration of these spinel ferrites.[4–6] It was determined that 
the resulting spinel ferrites have tunable SAR values, some-
what better than IONPs due to their larger coercivity values and 
wider hysteresis loop, which directly translates into the produc-
tion of more heat under AMF.[7] Additionally, despite the suc-
cess stories of IONP-based HT, it is often shown that, the efect 
of heat produced under HT alone is not suicient to achieve 
complete tumor suppression. HT is often combined with other 
therapies and most commonly with chemotherapies.[8] This 
is also the case in the clinical study discussed earlier, where 
the IONP-based HT was followed by radiotherapy or chemo-
therapy.[1] We have previously investigated this combination, 
IONC-based HT and chemotherapy utilizing doxorubicin.[9,10]
Among the mixed ferrites, cobalt ferrite nanoparticles 
(Co–Fe NPs), despite their high coercivity value about one order 
of magnitude larger than that of IONPs, are the least exploited 
material in biological studies, due to its well-documented toxicity 
proile given by the degrading cobalt ions.[11] In fact, only a handful 
of preclinical studies are available to date that demonstrate the 
use of Co–Fe NPs as hyperthermia agent for cancer therapy.[12,13] 
In most in vivo studies, the Co–Fe NPs were exploited as diag-
nostic tools pertaining to their outstanding T2 relaxivity traces 
in magnetic resonance imaging (MRI).[14,15] The well-established 
intrinsic toxicity of Co ions can be converted into a useful tool 
representing a cytotoxic agent acting similar to chemotherapeutic 
agent, by simply controlling the etching and the release of the Co 
from the MNP surface. The uptaken cobalt ferrite nanoparticles 
can undergo degradation within lysosome, at acidic pH, leading 
to slow etching and release of the included cobalt ions.[16,17] In 
fact, heavy metals and toxic elements are already in use in clinical 
chemotherapy.[18] Instead of using a separate cytotoxic agent, the 
use of Co–Fe NPs could potentiate delivery of toxic Co ions, as a 
form of chemotherapy to tumor cells.[19]
Motivated by these ideas, in this study, we aimed to dem-
onstrate the use of cubic-shaped cobalt ferrite nanoparticles 
(Co–Fe NCs) to exploit the dual therapy utilizing the heat pro-
duced by Co–Fe NCs in the AMF and the intrinsic toxic efects 
of Co ions released from the NPs following slow degradation in 
tumor microenvironment, for improved cancer therapy. We uti-
lized Co–Fe NCs with cubic edge size of 17 nm and compared 
it both in vitro and in vivo, with standard IONCs for eicacy in 
heat production and tumor suppression. We also investigated 
the long-term survival of the Co–Fe NCs in treated animals 
and proiled the biodegradation of the injected Co–Fe NCs in 
xenograft tumor model utilizing nude mice with A431 human 
epidermoid carcinoma. Despite a moderate heat temperature at 
the tumor and the expected cobalt cytotoxicity, we found that 
the Co–Fe NCs formed long chains comprising multiple nano-
cubes at the tumor site. The length of these chains increased 
under HT treatment. On the contrary, the IONCs did not form 
the nanoparticle chains under similar HT treatment conditions 
and failed to reduce tumor mass. This discrepancy in chain 
formation between the two nanocubes was further predicted 
by numerical calculations based on simple physical observa-
tions. In short, this article focuses on three considerations: two 
well-known behaviors of Co–Fe NCs, namely: 1) mild hyper-
thermia causing local heat damage and 2) the associated local 
intrinsic cobalt toxicity that can be controlled by site-speciic 
intratumoral injections and lastly a very unique property of Co–Fe 
NCs, and 3) the chain formation that can be increased upon HT. 
We propose this triple chemo-magnetomechanical heat damage 
therapy as novel multimodal therapy for cancer treatment.
In detail, cubic-shaped cobalt ferrite nanoparticles of 
stoichiometry Co0.65Fe2.35O4 (Co–Fe NCs) were prepared by a 
thermal-decomposition method and coated with poly(maleic 
anhydride-alt-1-octadecene)(PMAO) to render them water-soluble 
and usable for biological applications, following well-established 
procedures developed in our laboratory (Figure 1a).[5,20] The trans-
mission electron microscopy (TEM) images of water transferred 
Co–Fe NCs showed monodispersed particles with mean edge 
size of 17 ± 2 nm (Figure 1b; Figure S1, Supporting Information). 
The hydrodynamic size measured by DLS was 47 nm (0.08 PDI) 
indicating a uniform size distribution (Figure S2, Supporting 
Information). In order to compare the hyperthermia perfor-
mance of the Co–Fe NCs coated with PMAO, standard IONCs of 
similar size (17 ± 2 nm) were prepared and coated with the same 
polymer (Figure 1c).[3] To compare the heating eiciency of these 
nanocubes under AMF, SAR measurements were conducted at 
various frequencies (f: 105, 220, and 300 kHz) and ield (H: 12, 
16, 20, and 24 kA m−1) conditions. The SAR values of IONCs in 
aqueous solutions was comparatively higher than Co–Fe NCs 
at frequencies of 220 and 300 kHz, but at lower frequency con-
ditions (105  kHz and 20 kA m−1), the SAR of Co–Fe NCs was 
400 W g−1, which was twice higher than IONCs (200 W g−1; 
Figure  1d) within the biologically acceptable AMF limits (H·f 
value: 5 × 109 kA m−1 Hz−1).[21]
The complex dependence of SAR on frequency and ield is 
mainly due to the large diference in the efective anisotropy 
between both particle types (discussed in detail later). For the 
small-anisotropy IONCs, increasing the frequency leads to the 
development of a larger number of nanoparticles showing hys-
teresis and therefore increases hysteresis losses and the SAR; 
one can see this behavior in Figure  1d at all maximum ield 
values investigated. On the other hand, the SAR of the high-
anisotropy Co–Fe NCs is strongly ield dependent and weakly 
dependent on the frequency. It seems likely that this arises 
because the Co–Fe NC system is in the regime of minor hyster-
esis loops in small ields. In this regime, increasing frequency 
is compensated by a decrease in the area of the hysteresis loop, 
resulting in a weak frequency dependence. Increasing the ield 
will have the strong efect of moving the system toward full 
hysteresis, which consequently increases the SAR, consistent 
with the behavior shown in Figure 1d.
In vitro cytotoxicity of Co–Fe NCs was assessed using A431 epi-
dermoid carcinoma cells. The cells were exposed to two diferent 
concentrations of Co–Fe NCs (25 × 10−9 and 50 × 10−9 m) and com-
pared to the cytotoxicity of IONCs of same size, surface coating, 
and concentration. While both concentrations of IONCs showed 
no toxicity up to 72 h, the Co–Fe NCs began to exhibit mild toxicity 
at 24 h, which gradually increased for 72 h: 25% toxicity for 25 × 
10−9 m of Co–Fe NCs, and a 50% toxicity (lethal dose 50, LD50) for 
50 × 10−9 m Co–Fe NCs (Figure 1e). As expected, this conirms the 
toxic proile of polymer coated Co–Fe NCs compared to nontoxic 
IONCs, which proves that the toxicity is more likely due to the 
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Co ions in the Co–Fe NCs and not due to the size, shape, or the 
iron (Fe) moiety of the nanocubes.[22]
In the irst in vivo eicacy study, we aimed to understand 
the heating eiciency of the Co–Fe NCs to function as hyper-
thermia agents in a murine xenograft tumor model using nude 
mice and human A431 epidermoid carcinoma cells. Poly mer-
coated Co–Fe NCs ([Co+Fe] = 0.7 mg) were injected intratumor-
ally (i.t.) in the palpable tumor developed in the lank of the 
mice. I.t. injection was chosen in order to localize the toxicity of 
Co–Fe NCs and evaluate the HT eicacy with respect to IONCs 
(0.7 mg of Fe). The gallic acid PEG coated IONCs used as com-
parative standard in this study has been previously investi-
gated by our laboratory for its superior HT performance both 
in vitro and in vivo.[10] Given the high SAR value of the Co–Fe 
NCs under clinical HT conditions (105  kHz and 24 kA m−1; 
Figure  1c), we have chosen to use these alternating magnetic 
ield parameters for all in vivo studies hereafter (Figure 2a). In 
short, NPs were injected when the tumors were ≈80–100 mm3 
(day 0), followed by 30 min  HT cycles on day 0, day 1, and 
day 2, totaling 3× HT cycles on three consecutive days (HT1, 
HT2, and HT3). During the course of the 3× HT treatments, 
for animals i.t. injected with IONPs (TEM; Figure 2b) or Co–Fe 
NCs (TEM; Figure  2c), the temperature of the tumor (TTumor) 
and the temperature of the skin of the tail (away from tumor, 
TSkin) was monitored using an IR camera (Figure 2d). The dif-
ference between the temperature of the tumor and of the skin 
(∆T  = TTumor  − TSkin) was found to be about 6  °C for IONCs 
on HT1, but this decreased to about 3.5 °C on HT2 and HT3. 
On the contrary, Co–Fe NCs showed a ∆T of only 3 °C on HT1, 
but this value was maintained at HT2 and HT3. The observed 
reduced temperature and in turn SAR performances, for Co–
Fe NCs with respect to the same Co–Fe NCs in water media 
(Figure  1d) could be due to immobilization of the nanocubes 
in the viscous tumor/environment or to the strong interparticle 
interactions within the cellular environment (as also discussed 
later)[23], as it is known that interparticle interactions diminish 
the heat release of high anisotropy particles.[24]
Despite the unlikely prospect to reach the desired higher tem-
perature using the Co–Fe NCs, tumor growth was monitored for 
12 days after treatment initiation. The Co–Fe NCs with HT (Co–
Fe NCs + HT) help delay the tumor growth, although the tumor 
reducing property compared to its non-HT counterpart (Co–Fe 
NCs) or the IONCs with and without HT (IONCs and IONCs + 
HT, respectively) was not signiicant (Figure  2f). The results 
Figure 1. Characterization of cobalt ferrite nanocubes. a) A schematic representation of aqueous solution of poly(maleic anhydride-alt-1-octadecene) 
(PMAO) polymer-coated Co–Fe NCs compatible for biological application. b,c) TEM images of PMAO-coated Co–Fe NCs with mean sizes of 17 ± 2 nm 
(b) and PMAO-coated IONCs with mean sizes of 17 ± 2 nm showing a monolayer carpet of nanoparticles and the absence of aggregates (c). Scale bar rep-
resents 50 nm. d) SAR measurements at diferent ield intensities (12, 16, 20, 24, and 32 kA m−1) and frequencies (105, 220, and 300 kHz), showing higher 
SAR value for Co–Fe NCs at lower clinically relevant AMF conditions (105 kHz and 20 kA m−1) compared to IONCs. e) LDH cytotoxicity assay showing 
no toxicity for IONCs and signiicant intrinsic toxicity of Co–Fe NCs on A431 epidermoid carcinoma cells at 25 × 10−9 and 50 × 10−9 m concentrations.
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obtained with respect to IONCs + HT are comparable with pre-
viously reported in vivo study.[10] Importantly, an efective tumor 
reduction was never achieved when 18  nm IONP-based hyper-
thermia alone was used as a monotherapy platform.[10] Instead, 
intravenous injection of doxorubicin (combination therapy: 
IONCs + HT + Doxo) was required to increase the eicacy of 
IONC-based HT.[9]
Given the rather low heating proile associated with Co–Fe 
NCs under HT treatment, and the marginal improvement in 
delaying tumor growth, we proceeded to further investigate the 
reason behind this inconsistency. TEM images of the treated 
tumors at day 12 post-injections were analyzed to study the 
efect of HT within the ultrastructures of the cell. TEM images 
of both IONCs (Figure 3a,b) and Co–Fe NCs (Figure 3c,d) show 
Figure 2. Comparison of in vivo eicacy of Co–Fe NC and IONC-based hyperthermia. a) Schematic timeline representation of the treatment strategy. The 
black arrow represents particle injection (0.7 mg Co–Fe NCs or 0.7 mg IONCs) and the red arrows represent days of HT treatments (3× HT) using clinically 
acceptable AMF conditions (f: 110 kHz; H: 20 kA m−1). b,c) TEM images of ligand-exchanged IONCs with mean sizes of 18 ± 3 nm (b) and PMAO-coated 
Co–Fe NCs with mean sizes of 17 ± 2 nm (c) used for the in vivo experiments. Scale bar represents 50 nm. d) Infrared images of a mouse injected with 
IONCs and Co–Fe NCs during HT treatment at day 1 (HT1), day 2 (HT2), and day 3 (HT3). The white and black arrows highlight the temperature at tumor 
and the skin respectively, utilized to generate ∆T values. e) ∆T graph (∆T = TTumor − TSkin) plotted for HT1, HT2, and HT3 for animals injected with IONCs 
(orange bars) or Co–Fe NCs (red bars). f) Tumor growth curve showing the marginal reduction in tumor growth for animals injected with Co–Fe NCs 
and subjected to 3× HT (Co–Fe NCs + HT) compared to the other groups studied (Control, Co–Fe NCs alone, IONCs alone, and IONCs + HT). N = 6.
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presence of these nanoparticles within well-deined endosomal 
structures. This localization can potentially promote degrada-
tion of these nanocubes at acidic endosomal pH, particularly in 
the case of Co–Fe NCs releasing toxic cobalt within the tumor 
cells, leading to their destruction.[16,17] Also, the groups treated 
with IONCs and IONCs + HT did not show any unique align-
ment of nanocubes (Figure 3a,b). Unexpectedly the Co–Fe NCs 
structures found within the tumors, both with and without HT, 
were forming chain-like alignments (Figure  3c,d). To quan-
tify the chain formation, we analyzed the TEM images and 
determined the number of particles per chain in Co–Fe NCs 
and Co–Fe NCs + HT tissue samples using a MATLAB pro-
gram. The percentage of diferent number of chains formed 
per each group was determined and itted using a log-normal 
distribution. Notched box plot distributions of the number 
of nanocubes per chain (NCs/chain) in the Co–Fe NCs alone 
and the Co–Fe NCs + HT showed increased number of NCs/
chain for the latter than its non-HT counterpart. The Co–Fe 
NCs chains have a median of 4 NCs/chain and this distribu-
tion shifted to 7 NCs/chain after HT (Figure 3e), proving that 
Figure 3. Investigation of the chain formation of cubic shape Co–Fe NPs in vivo. a–d) Transmission electron microscopy images of tumors injected 
with IONCs (a,b) and Co–Fe NCs (c,d). Tumors injected with IONCs did not show any speciic NP arrangements without (a) or with (b) HT. Chain-like 
structures were evident in tumors injected with both Co–Fe NCs alone (c) and Co–Fe NCs + HT (d). All images represent analysis on tumors 12 days 
post-treatment and the scale bar represents 0.5 µm. e,f) MATLAB was used to determine the number of particles per chain in TEM images of Co–Fe 
NCs and Co–Fe NCs + HT. e) Notched box plot distribution of the number of NPs per chain in the Co–Fe NCs alone and the Co–Fe NCs + HT group 
highlighting a greater number of NPs per chain for the Co–Fe NCs + HT than its non-HT counterpart. Histogram showing the distribution of the 
number of NPs per chain in the Co–Fe NCs (green bars) and Co–Fe NCs + HT (red bars). The entire range is divided into bins of one nanocube width. 
f) The dashed line in the graph represents the log-normal distribution function that its the population of the two groups being studied, showing HT 
treatment favors the addition of further nanocubes to the already existing chains at the tumor.
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HT increases the number of nanoparticles in the chain. Also, 
this statement is further reinforced by the histograms showing 
the distribution of the NCs/chain in the Co–Fe NCs (green 
bars) and Co–Fe NCs + HT (red bars). The mode value (highest 
repeating number of cubes per chain) of the log-normal distri-
bution was 3.01 (3 cubes) for Co–Fe NCs and 4.9 (5 cubes) for 
Co–Fe NCs + HT (Figure 3f). Overall, the chains in the samples 
treated with HT had an augmented chain length (a 1.62-fold 
increase) with respect to the non-HT treated samples.
To determine if the chain length increase occurred immedi-
ately after the irst 30 min  of HT in the tumor, we emulated 
the in vivo HT setup in vitro using diferent % of glycerol or 
Matrigel, simulating a tumor-like environment (phantom) 
(Figures S3 and S4, Supporting Information). TEM images of 
the matrigel phantom clearly indicated the presence of chains 
after just one cycle of HT (Figure S4, Supporting Information). 
To the best of our knowledge, while the formation of chains 
has been reported in quite a few in vitro studies conducted in 
test tube setup containing the Co–Fe NPs, it has never been 
observed or reported in in vivo conditions at the tumor site, 
especially demonstrating increase in chain length post-HT 
under AMF.[19]
To understand if the chain formation is magnetically feasible 
under our experimental conditions for Co–Fe NCs (17 ± 2 nm) 
and is less feasible for IONCs of approximately similar cube 
edge (18 ± 3 nm), we have developed the following qualitative 
arguments. Namely, we consider the NP size dependence of the 
Néel and Brownian relaxation times, which are the main char-
acteristic timescales determining the physical behavior of Co–
Fe NCs and IONCs under a time-varying magnetic ield. Néel 
relaxation relates to thermal luctuations of magnetic moments 
of NPs and the corresponding Néel characteristic time is[25]
A
τ
π
τ=
Γ
Γe
N 0 1/2
 (1)
where τ0 = 1 ns is the attempt time, A  = 2 and Γ  = KV/kBT  
(the ratio of anisotropy energy to thermal energy) for NPs with 
uniaxial magnetocrystalline anisotropy, and A  = 4 and Γ  = 
K1V/4kBT  for NPs with cubic anisotropy. To a good approxima-
tion, the anisotropy is assumed to be uniaxial for IONCs with 
its value estimated as K  = 1.1  ×  105  erg cm−3 (Figures S5 and 
S6, Supporting information) and cubic for Co–Fe NCs with 
K1  =  2  × 10
6 erg cm−3. Brownian relaxation relates to positional 
rotational and translational luctuations of NPs with the rotational 
(τB) and translational (difusion, τdif) relaxation times deined as
V
k T
3
B
hyd
B
τ
η
=  (2)
R
k T
6
diff
2
hyd
B
τ
χ πη
=  (3)
where η is the viscosity of the embedding medium, Vhyd and 
Rhyd are the hydrodynamic volume and diameter, respectively, 
and χ is the characteristic difusion length (see Equation (S4) in 
the Experimental Section in the Supporting Information).
It is apparent that the formation of stable magnetic chains 
is expected when τN ≫ τB, τdif. This is because only under this 
condition the magnetic moments of NPs remain stable on the 
timescales of Brownian luctuations and magnetic dipolar inter-
action between the nanocubes can suiciently prevail and drive 
the physical assembly of nanocubes into chains. Therefore, in 
the following, we identify the parameter region where the τN 
dominates τB and τdif.
This is demonstrated in the bottom panel of Figure 4, which 
shows the dependence of these relaxation times versus the 
nanocube size and illustrates considerably diferent locations 
and slopes of the τN curves for Co–Fe NCs and IONCs. Namely, 
for Co–Fe NCs the τN becomes dominant for smaller nanocube 
edge size (≈12 nm) than for the IONCs (≈18 nm), and clearly 
this diference is to be attributed to diferent magnitudes of the 
magnetocrystalline anisotropy of these NPs. Moreover, when 
the experimental size distributions of NPs are taken into con-
sideration in the analysis (Figure  4, top), it becomes evident 
that while only 42% of IONCs are expected to be within the 
chaining region, i.e., the size region with dominant τN, and 
thus have the possibility to form chains, for Co–Fe NCs the 
whole NPs size distribution (100%) lies within the aggregation 
region. This shows that the likelihood of observing chaining for 
Co–Fe NCs is indeed signiicantly higher than for the IONCs, 
which corroborates our experimental observations.
The problem of chaining in magnetic nanoparticle systems 
has generally been investigated for spherical rather than cubic 
nanoparticles.[26] However, simple theoretical estimates can 
Figure 4. Bottom: Identifying the active part of the particle size distri-
bution, where the Néel relaxation time (τN, dotted lines) is longer than 
the Brownian translational and rotational relaxation times (τdif and τB, 
respectively, solid lines) of particles, in order to gauge the likelihood of 
chain formation for IONCs (Fe3O4: blue) and Co–Fe NCs (CoFe: brown). 
The relaxation times were calculated using Equations (1)–(3). Top: frac-
tions of the IONCs (42%) and Co–Fe NCs (100%) size distributions sus-
ceptible to chain formation.
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provide an initial insight into the relative likelihood of spher-
ical and cubic particles to form chains. This is based on the 
usual parameter for estimation of magnetic coupling strength, 
λ µ π= M V d k T( ) /(2 )0 s
2
cc
3
B , where MS  and V are the saturation 
magnetization and particle volume, respectively, and dcc  is the 
center-to-center interparticle separation distance. Considering 
that the interparticle distance is equal to the side L  = 17  nm 
plus twice the 2 nm thickness coating for the cubes, and for the 
sphere the particle diameter (d ≈ 21 nm derived by considering 
a spherical nanoparticle of the same volume of a nanocube 
particle of 17  nm in cube edge) plus again twice the particle 
coating thickness, it is readily obtained that the spherical geo-
metry results in signiicant reduction of the coupling strength, 
of about 41%. Thus, for particles of the same size, spherical 
shape appears less favorable for chain formation.
We can also comment on the fact that longer Co–Fe NC 
chains are observed upon the exposure to alternating magnetic 
ield. First, we observe in our experiments random chain orienta-
tion with no apparent tendency toward a preferential alignment 
along the applied ield direction. One feasible way the chains can 
increase their average length is through the action of stray dipolar 
magnetic ields emanating from the already formed chains. 
Subjecting such chains to an applied magnetic ield results, on 
average, in their increased thermal stability, especially for chains 
oriented away from the perpendicular direction with respect to 
the applied ield. The increased thermal stability enhances the 
stray dipolar ields, thereby increasing the likelihood of attracting 
additional particles toward the ends of the chains. Note that this 
efect is expected to be the strongest for chains oriented along the 
applied ield. The second and more subtle efect that may lead 
to chain growth can result from the (moderate hyperthermic) 
temperature increase of the environment. Such a temperature 
increase will enhance the Brownian difusion of NPs, thereby 
increasing the likelihood of NP attraction toward the chains and 
promoting the increase in chain length. Although the tempera-
ture increase will also lead to reduced thermal stability of chains, 
this efect is less dominant as demonstrated in Figure S7 in the 
Supporting Information.
Having observed the presence of chains only for Co–Fe NCs, 
a long-term in vivo study was conducted following the same 
experimental scheme utilized earlier, to verify the persistence of 
chain formations and the prolonged cobalt toxicity, which could 
produce tumor reduction and longer survival (Figure  5a). For 
this study, we focused only on the eicacy of Co–Fe NCs with 
or without HT. Consistent with our previous observations, the 
HT treatments increased temperature at the tumor site by few 
degrees (IR images in Figure S8 in the Supporting Informa-
tion). Digital photographs taken on day 0 and day 15 for control 
animals show an increase in tumor size, whereas Co–Fe NCs 
treatment reduced tumor size and Co–Fe NCs + HT treatment 
completely suppressed the tumor by day 30 (Figure 5b). I.t. injec-
tion of Co–Fe NCs alone signiicantly delayed the growth of 
tumors compared to untreated animals (Control), but this was 
not suicient to completely eradicate tumor growth, as indicated 
by slow but gradual increase of tumor volume after 30 days. 
Instead, tumors treated with Co–Fe NCs followed by 3× HT 
(Co–Fe NCs + HT) showed tumor reduction within 30 days with 
no tumor recurrence up to 200 days post-treatment (Figure 5c). 
In addition, for the same Co–Fe NCs + HT group the survival 
rate was signiicantly higher than all the other groups studied, 
showing disease-free survival of up to 200 days (7 months). 
Meanwhile, the Control group and Co–Fe NCs group without the 
efects of HT succumb to disease much earlier with maximum 
survival rate of 22 and 30 days, respectively (Figure 5d).
Interestingly, TEM images of tumor tissues at day 30 con-
sistently showed long chain formation (Figure  5e,f ), indi-
cating that the nanocube–nanocube interactions is strong and 
once formed, they persist for a longer period. The histopatho-
logical studies at day 30 conducted on the tumor tissue of ani-
mals treated with Co–Fe NCs (with or without HT) showed 
that the NPs were present inside the tumor, indicated by the 
Prussian blue staining (Figure  5g,h;  Figure S9, Supporting 
Information). The Co–Fe NCs + HT group showed a swirling 
movement of nanocubes from the point of injection (center of 
the tumor) to the tumor periphery, a phenomenon previously 
observed due to the applied AMF (Figure  5h).[10] This data 
suggests that the injected Co–Fe NCs, already forming chains, 
could cause mechanical damage to the tissue while moving 
from the point of injection to the tumor periphery during 
the HT cycles (chain length increases with HT and can cause 
more damage). The presence of an almost impermeable outer 
viable collagenous layer at the tumor periphery is one of the 
main reasons that the tumor tissues thrive. While the growing 
tumor gets necrotic in the center, this outer layer containing 
viable cells and enriched angiogenesis at these sites, makes 
the tumor grow in volume. In addition, this thick layer and 
its tight arrangement of cellular architecture in a collagen rich 
environment protects the inner tumor cells from incoming 
drugs and other therapies.[27] In this case, the i.t. injection 
ensured that the particles were delivered in a controlled 
manner inside the tumor, minimizing nonspeciic cobalt 
toxicity. Also, i.t. injection is an acceptable palliative care for 
cancer patients.[28] The outer collagen-rich layer of the Co–Fe 
NCs + HT (Figure 5h), which is indicated by a fast red stained 
collagen (darker pink) and cells (pink) in the outer layer, was 
almost completely absent (more toxicity at the periphery 
leading to stroma destruction), while it was still viable in case 
of the Co–Fe NCs alone (Figure  5g).  This complete destruc-
tion of the outer tumor membrane could also contribute to 
the complete tumor reduction and lack of recurrence in the 
Co–Fe NCs + HT treated animals (Figure 5c).
A major concern when dealing with nanoparticles that con-
tain a toxic element is the biodistribution proile. Among mag-
netic nanoparticles, the biodegradation proile of IONPs is 
among the most investigated HT agents.[29] Although few in 
vivo works on Co–Fe NPs of diferent size and shape than the 
one reported here, have shown successful tumor reduction, 
these studies failed to track the fate of these nanoparticles post-
treatment completion.[13,14] To address this concern, we measured 
the elemental amount of Fe and Co in tumor (site of injection) 
and spleen. Indeed, a recent study showed that i.t. injected 
Co–Fe NPs can be tricked into being eliminated via the ferritins 
following the same method our body uses to eliminate the Fe 
ions through the spleen.[17] The tumor and spleen of treated ani-
mals were analyzed as and when they reached their endpoint and 
thus, we were able to track the fate of Co–Fe NCs from day 
20 (shortest survival) up to day 80 (longest survival for tumor-
bearing animal) post-HT using ICP-MS elemental analysis 
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(Figure 6). The tumors and spleens showed diferent levels of 
both Fe and Co depending on days following the treatment. It 
is interesting to notice the reduction in Fe levels in tumor over 
days and subsequent increase of the same in spleen, indicating 
the elimination of Fe from injected site (Figure  6a,c). For Co, 
the same trend was observed (Figure  6b,d). Decrease in Co 
levels in tumor followed a gradual increase of the same element 
in spleen. For the Co–Fe NCs + HT group, the amount of Co in 
the spleen gradually increased from 2 to 3 µg on the irst few 
days post-treatment to about 17  µg at 80 days post-treatment 
(Figure 6d). This low dose of Co could explain the absence of 
physical or psychological changes (i.e., no suferings) in ani-
mals treated with Co–Fe NCs (no signiicant changes in weight 
was recorded throughout the course of this study; Figure S10, 
Supporting Information).
TEM micrographs of tumors, spleens, and livers of animals 
intratumorally injected with Co–Fe NCs showed evidence of 
nanocubes presence only at the tumor on day 10 and day 30 
post-particle injection while no sign of nanocubes were 
observed in liver and spleen (Figures S11 and S12, Supporting 
Information). Remarkably, the size and shape of the Co–Fe 
NCs in the tumor at day 30 was diferent than that at day 10 
and that of the original nanocubes themselves. In fact, meas-
uring these morphological changes as a function of change in 
size and observed number of particles, we noticed signiicant 
diferences in mean size (nm) and the total number of these 
deformed Co–Fe NCs on day 30 compared to day 10 (Figure S13, 
Supporting Information).
To verify the intrinsic toxicity of cobalt in Co–Fe NCs, an in 
vivo experiment was performed by replacing the cubic-shaped 
Figure 5. A long-term study of in vivo HT eiciency of Co–Fe NCs. a) Schematic timeline representation of the treatment strategy. b) Photographic 
comparison between the control, untreated animal (Control: day 0 and day 15) and the animal treated with Co–Fe NCs alone and Co–Fe NCs + HT, 
showing the reduction and complete elimination of the tumor 30 days post-treatment, respectively. The images in the boxes show enlarged image of 
the treated tumor. c) Tumor growth curve showing the complete elimination of the tumor, and no recurrence up to 200 days for animals treated with 
Co–Fe NCs + HT. d) A Kaplan–Meier survival plot demonstrating the highest survival rate for animals treated with Co–Fe NCs + HT for up to 200 days 
post-treatment compared to other groups with a maximum survival rate of up to only 30 days. e,f) TEM images of tumors injected with Co–Fe NCs 
proving persistent chain-like structures even at day 30 post-treatment for both Co–Fe NCs alone (e) and Co–Fe NCs + HT (f). g,h) Light microscopy 
images of tumor slices obtained from groups treated with Co–Fe NCs alone (g) and Co–Fe NCs + HT (h), showing the presence of the injected NPs 
and a complete absence of stroma in the latter case. The NPs are shown in blue using Prussian blue staining; collagen stained in dark-pink and cells 
in light-pink due to Fast Red staining. Scale bars in (g) and (h) represent 0.5 cm.
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Co–Fe NPs with an equivalent dose (single or multiple doses) of 
cobalt ions, injected i.t. in the form of a cobalt chloride (CoCl2) 
salt (Figure S14, Supporting Information). Tumor growth showed 
no signiicant decrease compared to Control group, demon-
strating that cobalt toxicity by itself cannot act as a potential 
mono therapy. Elemental analysis on day 20 of CoCl2 injected ani-
mals showed majority of the Co ions in tumor (site of injection; 
0.5 µg and 2.5 µg Co g−1 of tissue for single and multiple dose, 
respectively) and marginal increase (less than 0.5 µg  Co g−1 of 
tissue) was seen at liver, kidney, and heart. No change in body 
weight of animals was seen proving tolerance toward injected 
CoCl2 amounts (Figure S14, Supporting Information).
Overall, our study demonstrates that Co–Fe NCs can be used as 
an efective platform for a synergistic multimodal cancer therapy 
based on the magnetic hyperthermia in a nonconventional way. 
Indeed, the enhanced treatment outcome is due to multiple coex-
isting efects. First, Co–Fe NCs act as a mild hyperthermia agent, 
increasing the tumor temperature causing heat damage to the 
cancer cells. Second, the local injection helps maintain the Co–Fe 
NCs for a prolonged period within the tumor site, allowing for the 
gradually released cobalt to cause a slow yet potent toxicity against 
cancer cells. Indeed, the amphiphilic polymer coating enables 
the slow degradation of nanocubes within the tumor, preventing 
systemic toxicity during the elimination step. Third, we have 
demonstrated that only Co–Fe NCs tend to form chain-like struc-
tures, an efect that was further enhanced after HT. This phe-
nomenon is observed for the irst time at the tumor site in an in 
vivo study, that is further enhanced under an externally triggered 
remote magnetic source. Further, TEM analysis of the tumors 
showed that the AMF-induced chain formation was particular for 
Co–Fe NCs and not for IONCs. This result was further substanti-
ated by a mathematical model suggesting that the large anisotropy 
of Co–Fe NCs renders them less susceptible to Néel relaxation 
than cubic shaped IONPs of similar size and shape, leading to 
stable magnetization states thus promoting the chain formation. 
In relation to the histology data demonstrating the movement of 
these particles from point of injection to the tumor periphery and 
combining it with visible chains in TEM images, we speculate 
that the collective migration of these chains under AMF could 
give rise to tumor reduction due to mechanical damage.
To enhance the toxic efects of Co–Fe NCs, other parameters 
may play key roles. For instance, a time lag (24–48 h) between 
Co–Fe NCs intratumoral injection and the time of application 
of HT treatment or the number of HT cycles to help grow the 
chain length further, can improve the synergy of the proposed 
multimodal therapy. The tuning of these parameters may help 
to reduce the dose of Co–Fe NCs, thus minimizing material 
side efects while maximizing therapeutic outcome. Further 
Figure 6. Proiling elimination of cobalt ferrite nanocubes at endpoint. a–d) ICP-MS elemental analysis of tumor and spleen post-treatment for Co–Fe 
NCs alone (a: Fe; b: Co) and Co–Fe NCs + HT (c: Fe; d: Co) showing consistent decrease of Fe and Co from tumor and simultaneous elimination of 
the same in spleen. The dashed lines represents a nonlinear (exponential) it and respective R2 values are listed above each graph.
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investigations by testing these proposed parameters to improve 
the therapeutic outcome of this platform will be explored in 
future studies.
In conclusion, this study provides a new take on spinel 
mixed ferrites tailoring magnetic performance for biological 
application and encourages researchers to exploit both the 
intrinsic toxicity of included elements and unique unexplored 
physical mechanisms like chain formation under AMF, here 
observed, as a mean to provide tumor damage.
Experimental Section
Cell Culture: A431 epidermoid carcinoma cells (ATCC CRL-1555TM) 
were cultured using Dulbecco’s modiied Eagle medium (DMEM) media 
supplemented with 10% fetal bovine serum, 2% penicillin–streptavidin, and 
1% l-glutamine (GibcoTM) under 37 °C, 5% CO2, and 95% relative humidity.
Animal Model: Pathogen-free 8 week old female immunodeicient 
athymic NMRI nude mice, purchased from Charles River laboratories, 
were used for all the procedures. They were housed in IVC cages in a 
temperature-controlled room with a 12/12 h dark/light cycle, with ad 
libitum access to water and food. 1.5 × 106 A431 epidermoid carcinoma 
cells in 100 µL  sterile saline were injected subcutaneously in the lank 
of each animal to induce the needed xenograft model. The tumor 
dimensions were recorded every alternate day using a caliper, and the 
tumor volumes were calculated using the formula: V  = Dd2/2, where 
D is the longest diameter of the tumor mass and d is the smallest 
diameter that is perpendicular to D. When the tumor volume reached 
≈80–100 mm3, the animals were distributed into diferent groups using 
a computer-generated randomization procedure. All animal experiments 
were performed in full compliance with Italian law d.lgs 116/92 (EU 
Directive 2010/63/EU for animal experiments) and the Istituto Italiano 
di Tecnologia (IIT) Ethical Committee. The animals’ health and level of 
comfort were regularly checked by a veterinarian.
Short-Term Study Experiment Groups: The Control group (N = 6) was 
a group of untreated animals. The IONCs (N  = 6) group was animals 
injected intratumorally with 50 µL  of 14 g L−1 iron-oxide nanocubes 
(0.7 mg  [Fe]/mice). The IONCs + HT (N = 6) group consisted of mice 
with tumor that was injected intratumorally with 50 µL  of 14 g L−1 
IONCs, and they were also subjected to 3 cycles of HT. The Co–Fe NCs 
(N = 6) group comprised animals that were injected intratumorally with 
50 µL of 14 g L−1 cobalt ferrite nanocubes (0.7 mg [Fe + Co]/mice). The 
Co–Fe NCs + HT (N = 6) group consisted of animals that were injected 
intratumorally with 50 µL  of Co–Fe NCs (0.7 mg  [Fe + Co]/mice), and 
they were also subjected to 3 cycles of HT. During the tumor cell and 
particle injection procedures, the animals were anesthetized using a gas 
anesthesia system with isoluorane and oxygen mixture, and the tumors 
were immobilized using a sterile tweezer for a controlled intratumoral 
injection of the NPs. All the particle samples that were used for the in 
vivo experiments were prepared under sterile conditions, and they were 
UV-sterilized for 6 h prior to injection.
Long-Term Experiment Groups: Here, the amount of Co–Fe NCs 
injected intratumorally was manipulated according to individual tumor 
volume (0.7 mg  NPs/80 mm3 volume of tumor). The Control group 
(N = 6) consisted of animals with an untreated tumor (no particles or 
HT). The Co–Fe NCs (N = 6) group included mice injected intratumorally 
with Co–Fe NCs alone. The Co–Fe NCs + HT (N = 6) group comprised 
animals injected intratumorally with Co–Fe NCs, and then subjected to 
3 cycles of HT. During the particle injection procedures, the animals 
were anesthetized using gas anesthesia (isolurane and oxygen mix), 
and the tumors were immobilized using a sterile tweezer for a controlled 
injection of the NPs within the tumor.
Hyperthermia Therapy and Temperature Monitoring: 5 min after 
the NPs were injected, in both short- and long-term experiments, 
the animals in group with HT were subjected to AMF, which was 
generated by a MagneTerm AC system (Nanotherics, Corp), for 30 min 
(HT1). The animals were then subjected to two more cycles of HT, 
each of which lasted 30 min (HT2 and HT3), over the next 2 days. 
The ield and frequency of the AMF used was 20 kA m−1 and 110  kHz, 
respectively. During the course of HT, the animals were anesthetized 
using intraperitoneal injection of ketamine/xylazine mixture prepared 
by the inhouse veterinarian that lasted for 30–40 min  (course of HT 
treatments). The temperature of the mouse’s skin and tumor was 
monitored using an IR camera (Fluka, Inc.) throughout the course of 
HT therapy. All the images were processed by Fluka Software, which was 
provided by the manufacturer. The animals experiencing HT treatments 
were observed under IR lamp until they regained consciousness and 
mobility and then moved to their respective cages.
Endpoints: All animals were sacriiced in a humane manner 12 days 
postparticle injection and HT1 in the case of the short-term experiment. 
The humane endpoint for the long-term experiment was when at least 
one diameter of the tumor reached 2 cm in length (NIH guidelines).
Statistics: For LDH assay (Figure  1d), 2-way analysis of variance 
(ANOVA) using Tukey’s multiple comparison test was used to analyze 
signiicance between each group at diferent time points. Statistical 
signiicance for tumor growth curve analysis (Figure 5c) was calculated 
using one-way ANOVA (Tukey’s multiple comparison test). P value was 
0.0023 and 0.0004 between CTRL and Co–Fe NCs, CTRL, and Co–Fe NCs 
+ HT, respectively. Statistical signiicance for survival study (Figure 5d) 
was calculated using log-rank (Mantel–Cox) test. P value was 0.0367 
and 0.0033 between CTRL and Co–Fe NCs, CTRL, and Co–Fe NCs + HT, 
respectively. P values were calculated using Prism GraphPad, GP: 0.1234 
(ns), 0.0332 (*), 0.0021 (**), 0.0002 (***), and <0.0001 (****).
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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